Prakt. lékáren. 2011; 7(3): 103-105
Iloperidone
- 1 Psychiatrická klinika LF UK v Plzni
- 2 Fachklinik Furth im Wald
Iloperidone is an atypical antipsychotic drug of a group referred to as SDAs (serotonin/dopamine receptor antagonists). This antipsychotic
was approved by the FDA for the treatment of schizophrenia in the United States in 2009; it is still not available in the Czech Republic.
Iloperidone is as effective as haloperidol in the treatment of schizophrenia. It has a low rate of extrapyramidal and metabolic adverse
effects. Common adverse effects mainly include orthostatic hypotension, dizziness, and a dose-dependent QTc interval prolongation
early in the treatment. The efficacy and tolerance of iloperidone were evaluated in relation to genetic markers. Several nucleotide polymorphisms
have been found to be associated with a higher efficacy and an increased risk of QTc interval prolongation.
Keywords: iloperidone, antipsychotics, schizophrenia, pharmacokinetics, efficacy
Published: June 1, 2011 Show citation
References
- Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotics. Int J Clin Pract 2009; 63(8): 1237-1248.
Go to original source... 
Go to PubMed... - Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2010; 64: 707-718. Go to original source... Go to PubMed...
- Mohr P. Iloperidon: variace na obehrané téma anebo první aplikace personalizované medicíny v psychiatrii? Psychiatrie 2010; 14(3): 153-157.
- Vanda Pharmaceuticals. Fanapt (iloperidone tablets) Prescribing information. Revised 12/2010.
- US Food and Drug Administration. Fanapt (iloperidone), Drug Approval Package, NDA 022192, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022192s000TOC.cfm, June 2009.
- Kongsamut S, Roehr JE, Cai J. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 1996; 317: 417-423. Go to original source... Go to PubMed...
- Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: A broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001; 25: 904-914. Go to original source... Go to PubMed...
- Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther 2010; 4: 33-48. Go to original source... Go to PubMed...
- Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acutephase pivotal trials. J Clin Psychopharmacol 2008; 28(2 Suppl 1): 12-19. Go to original source... Go to PubMed...
- Cutler AJ, Kalali AH, Weiden PJ, et al. Four week, doubleblind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2008; 28(2 Suppl 1): 20-28. Go to original source... Go to PubMed...
- Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008; 28(2 Suppl 1): 29-35. Go to original source... Go to PubMed...
- Corbett R, Griffiths L, Shipley JE, et al. Iloperidone: preclinical profile and early clinical evaluation. CNS Drug Rev 1997; 3: 120-147. Go to original source...
- Borison RL, Huff FJ, Griffiths L. Efficacy of 4 mg/day and 8 mg iloperidone administered to schizophrenic patients for 42 days. Psychopharmacol Bull 1996; 32: 416.
- Mucke HA, Castaner J. Iloperidone. Drug Future 2000; 25: 29-40. Go to original source...
- Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008; 28(2 Suppl 1): 4-11. Go to original source... Go to PubMed...
- Volpi S, potkin SG, Malhotra AK, Licamele L, Lavedan C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009; 70: 801-809. Go to original source... Go to PubMed...
- Thompson A, Lavedan C, Volpi S. Absence of weight gain association with the HTR2C-759C/T polymorfism in patients with schizophrenia treated with iloperidone. Psych Res 2010; 175: 271-273. Go to original source... Go to PubMed...
- Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, Lannan R, Thomson A, Wolfgang CD, Polymeropoulos MH. Association of the NPAS3 gene anf five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009; 14: 804-819. Go to original source... Go to PubMed...